相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hutchinson-Gilford progeria syndrome: Rejuvenating old drugs to fight accelerated ageing
Solenn M. Guilbert et al.
METHODS (2021)
Discovery of Lonafarnib-Like Compounds: Pharmacophore Modeling and Molecular Dynamics Studies
Shailima Rampogu et al.
ACS OMEGA (2020)
A Phase 2 Study of Peginterferon Lambda, Lonafarnib and Ritonavir for 24 Weeks: End-of-Treatment Results from the LIFT HDV Study
Christopher Koh et al.
JOURNAL OF HEPATOLOGY (2020)
Transient introduction of human telomerase mRNA improves hallmarks of progeria cells
Yanhui Li et al.
AGING CELL (2019)
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study
Cihan Yurdaydin et al.
HEPATOLOGY (2018)
Subanalysis of the LOWR HDV-2 study reveals high response rates to Lonafarnib in patients with low viral loads
C. Yurdaydin et al.
JOURNAL OF HEPATOLOGY (2018)
An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome
Karim Harhouri et al.
NUCLEUS (2018)
An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome
Karim Harhouri et al.
NUCLEUS (2018)
A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis - end of study results from the LOWR HDV-3 study
C. Koh et al.
JOURNAL OF HEPATOLOGY (2017)
Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts
Diana Gabriel et al.
ONCOTARGET (2017)
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial
Christopher Koh et al.
LANCET INFECTIOUS DISEASES (2015)
Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome
Leslie B. Gordon et al.
CIRCULATION (2014)
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment
Nicole J. Ullrich et al.
NEUROLOGY (2013)
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome
Leslie B. Gordon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar)
A Ghosal et al.
DRUG METABOLISM AND DISPOSITION (2006)
Farnesyl transferase inhibitors
AD Basso et al.
JOURNAL OF LIPID RESEARCH (2006)
Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome
BC Capell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
分享论文
